Australia’s national airline has revealed that all international air travellers will need to provide evidence that they have received a Covid-19 vaccine before travelling on their services.
Qantas made the announcement earlier this month, with CEO Alan Joyce labelling it “a necessity” and calling on other airlines to follow suit.
Speaking to Australia’s Nine News Network this week, Joyce said that he believes more airlines will adopt the plans over the coming weeks and months - as the quest to vaccinate the population against the virus steps up.
The Irishman said: “We are looking at changing the terms and conditions to say for international travelers that we will ask people to have the vaccination before they get on the aircraft.
“I think that's going to be a common thing, talking to my colleagues in other airlines around the globe.
“It will require a lot of work and present plenty of logistical challenges, but certainly for international visitors coming out and people leaving Australia, we think that it’s a necessity.
“What we are looking at is how you can have a vaccination passport, an electronic version of it, that certifies what the vaccine is, is it acceptable to the country you are traveling to.”
It comes at a promising time for researchers working on a vaccine for the virus, after trials of the AstraZeneca/Oxford University solution showed up to 90 percent efficacy when two doses were administered.
The vaccine is also some £17 a dose cheaper than others developed so far, and is fridge stable to make it easily transported to hotter and more remote locations.
Professor Sarah Gilbert, leading the research, said: “The announcement this week takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by Covid-19.
“We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multinational effort, which will reap benefits for the whole world."
The English based pharmaceutical giant says the vaccine was 70 percent effective overall, but there were differences between two dosing regimens. One was 90 percent effective and the other 62 percent.
In a statement AstraZeneca said: “More data will continue to accumulate, and additional analysis will be conducted, refining the efficacy reading and establishing the duration of protection.”
If you are thinking about moving abroad for a job in the medical sector then, register with Odyssey Recruitment today and we could help you find the perfect job!